Principal Investigator: Shi Fang Yan, MD
I am a leading investigator of the molecular and cellular mechanisms of diabetic complications, including ischemic disorders and vascular disorders. The development of my research interests has been an exciting journey so far. Following my initial findings of Early growth response-1 (Egr-1) as a central mediator of stress responses in hypoxia and ischemia, my major focuses are on the dissection of the contribution of the interplay between the three key molecules linked to vascular stress, including Egr-1, protein kinase C-beta (PKC-β), and receptor for advanced glycation end-products (RAGE). I was awarded two RO1 grants from the National Heart, Lung and Blood Institute (NHLBI) for my work on the role of PKCβ, Egr-1 and its downstream targets in atherosclerosis and restenosis.
This work has important implications for the management of atherosclerosis and complications of angioplasty in human subjects. In addition, I have collaborated with Drs. Ann Marie and Ravi Ramasamy for the past 15 years; we have been awarded a competitive renewal of a program project grant by the NHLBI and a new program project grant by the NIA in the past years. My ongoing projects have been extended from heart and aortic arch vasculature to diabetic limb ischemia because atherosclerotic blockages found in the lower extremity which can cause either acute or chronic ischemia.
I have published more than 100 research/review articles in medical journals, including Nature Medicine, Journal of Clinical Investigation, PNAS, Circulation Research, FASEB, JBC, Atherosclerosis and etc. I was the winner of the Council's 2000 Cournand and Comroe Young Investigator Award and a best poster award (2005) at the American Heart Association (AHA). My research group has presented its work at national meetings, such as those of the AHA, ATVB and FASEB.